NovAccess Global Inc. (XSNX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.76 Million USD | -899.23% |
| 2022 | 591.18 Thousand USD | 120.45% |
| 2021 | -2.89 Million USD | 57.5% |
| 2020 | -6.8 Million USD | -390.14% |
| 2019 | 2.34 Million USD | 159.05% |
| 2018 | -3.96 Million USD | -696.01% |
| 2017 | -498.66 Thousand USD | -105.32% |
| 2016 | -242.86 Thousand USD | 81.61% |
| 2015 | -1.32 Million USD | 32.27% |
| 2014 | -1.94 Million USD | 22.7% |
| 2013 | -2.52 Million USD | -62.19% |
| 2012 | -1.55 Million USD | -39.15% |
| 2011 | -1.11 Million USD | 49.44% |
| 2010 | -2.21 Million USD | 79.21% |
| 2009 | -10.63 Million USD | -161.99% |
| 2008 | -4.05 Million USD | -214.77% |
| 2007 | -1.28 Million USD | 62.54% |
| 2006 | -3.44 Million USD | -145.71% |
| 2005 | -1.4 Million USD | 7.17% |
| 2004 | -1.5 Million USD | -934.54% |
| 2003 | -145.86 Thousand USD | -208.41% |
| 2002 | -47.29 Thousand USD | -115.48% |
| 2001 | 305.48 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -492.59 Thousand USD | -137.79% |
| 2024 Q1 | 1.3 Million USD | 173.75% |
| 2024 Q3 | -936.33 Thousand USD | -90.08% |
| 2023 FY | -4.72 Million USD | -899.23% |
| 2023 Q1 | -2.63 Million USD | -220.76% |
| 2023 Q4 | -1.76 Million USD | -126.73% |
| 2023 Q3 | -779.63 Thousand USD | -271.82% |
| 2023 Q2 | 453.76 Thousand USD | 117.24% |
| 2022 Q4 | 2.17 Million USD | 66.05% |
| 2022 Q1 | -143.3 Thousand USD | -244.93% |
| 2022 Q2 | -1.77 Million USD | -1140.0% |
| 2022 Q3 | 1.31 Million USD | 173.85% |
| 2022 FY | 591.18 Thousand USD | 120.45% |
| 2021 Q4 | 98.87 Thousand USD | 104.71% |
| 2021 Q1 | 155.11 Thousand USD | 102.09% |
| 2021 Q3 | -2.09 Million USD | -213.4% |
| 2021 FY | -2.89 Million USD | 57.5% |
| 2021 Q2 | -669.2 Thousand USD | -531.43% |
| 2020 FY | -6.8 Million USD | -390.14% |
| 2020 Q3 | 708.1 Thousand USD | 1737.17% |
| 2020 Q2 | 38.54 Thousand USD | 137.91% |
| 2020 Q1 | -101.66 Thousand USD | -111.1% |
| 2020 Q4 | -7.41 Million USD | -1147.19% |
| 2019 FY | 2.34 Million USD | 159.05% |
| 2019 Q1 | 1.4 Million USD | -50.28% |
| 2019 Q2 | 482.36 Thousand USD | -65.69% |
| 2019 Q3 | -460.44 Thousand USD | -195.45% |
| 2019 Q4 | 915.96 Thousand USD | 298.93% |
| 2018 Q3 | -6.27 Million USD | -1265.75% |
| 2018 Q4 | 2.82 Million USD | 145.09% |
| 2018 Q1 | -66.54 Thousand USD | 80.21% |
| 2018 Q2 | -459.2 Thousand USD | -590.08% |
| 2018 FY | -3.96 Million USD | -696.01% |
| 2017 Q4 | -336.28 Thousand USD | -110.39% |
| 2017 FY | -498.66 Thousand USD | -105.32% |
| 2017 Q3 | -159.83 Thousand USD | -584.77% |
| 2017 Q2 | 32.97 Thousand USD | 192.85% |
| 2017 Q1 | -35.51 Thousand USD | 73.0% |
| 2016 Q2 | 160.46 Thousand USD | 610.65% |
| 2016 Q1 | -31.42 Thousand USD | 92.57% |
| 2016 Q3 | -240.4 Thousand USD | -249.82% |
| 2016 Q4 | -131.5 Thousand USD | 45.3% |
| 2016 FY | -242.86 Thousand USD | 81.61% |
| 2015 FY | -1.32 Million USD | 32.27% |
| 2015 Q4 | -422.73 Thousand USD | -559.02% |
| 2015 Q3 | -64.14 Thousand USD | 92.51% |
| 2015 Q2 | -856.88 Thousand USD | -3805.93% |
| 2015 Q1 | 23.12 Thousand USD | 105.87% |
| 2014 Q4 | -393.88 Thousand USD | -218.06% |
| 2014 Q1 | -1.05 Million USD | -51.65% |
| 2014 FY | -1.94 Million USD | 22.7% |
| 2014 Q2 | -375.46 Thousand USD | 64.47% |
| 2014 Q3 | -123.83 Thousand USD | 67.02% |
| 2013 FY | -2.52 Million USD | -62.19% |
| 2013 Q4 | -696.8 Thousand USD | -134.6% |
| 2013 Q3 | -297.01 Thousand USD | 70.12% |
| 2013 Q2 | -993.92 Thousand USD | -85.91% |
| 2013 Q1 | -534.63 Thousand USD | -167.14% |
| 2012 Q4 | -200.13 Thousand USD | 67.61% |
| 2012 FY | -1.55 Million USD | -39.15% |
| 2012 Q3 | -617.92 Thousand USD | -114.05% |
| 2012 Q2 | -288.68 Thousand USD | 35.63% |
| 2012 Q1 | -448.45 Thousand USD | -47.0% |
| 2011 Q3 | -289.72 Thousand USD | -114.31% |
| 2011 Q1 | -387.67 Thousand USD | -14.29% |
| 2011 Q2 | -135.18 Thousand USD | 65.13% |
| 2011 Q4 | -305.07 Thousand USD | -5.3% |
| 2011 FY | -1.11 Million USD | 49.44% |
| 2010 FY | -2.21 Million USD | 79.21% |
| 2010 Q2 | -635.94 Thousand USD | -17.09% |
| 2010 Q3 | -692.19 Thousand USD | -8.85% |
| 2010 Q1 | -543.14 Thousand USD | 79.4% |
| 2010 Q4 | -339.19 Thousand USD | 51.0% |
| 2009 Q2 | -679.02 Thousand USD | 45.22% |
| 2009 Q4 | -2.63 Million USD | 56.64% |
| 2009 Q3 | -6.07 Million USD | -795.31% |
| 2009 Q1 | -1.23 Million USD | -60.13% |
| 2009 FY | -10.63 Million USD | -161.99% |
| 2008 Q4 | -774.11 Thousand USD | -12.66% |
| 2008 Q3 | -687.14 Thousand USD | 14.22% |
| 2008 Q2 | -801.05 Thousand USD | 58.17% |
| 2008 Q1 | -1.91 Million USD | -906.68% |
| 2008 FY | -4.05 Million USD | -214.77% |
| 2007 Q2 | -447.94 Thousand USD | 23.25% |
| 2007 Q3 | -495.63 Thousand USD | -10.65% |
| 2007 Q4 | 237.38 Thousand USD | 147.89% |
| 2007 FY | -1.28 Million USD | 62.54% |
| 2007 Q1 | -583.68 Thousand USD | 20.21% |
| 2006 Q3 | -1.12 Million USD | -103.35% |
| 2006 Q4 | -731.49 Thousand USD | 34.77% |
| 2006 Q2 | -551.47 Thousand USD | 65.44% |
| 2006 Q1 | -1.59 Million USD | -113.14% |
| 2006 FY | -3.44 Million USD | -145.71% |
| 2005 Q1 | -164.88 Thousand USD | 87.13% |
| 2005 Q2 | -205.11 Thousand USD | -24.4% |
| 2005 Q3 | -282.24 Thousand USD | -37.6% |
| 2005 FY | -1.4 Million USD | 7.17% |
| 2005 Q4 | -748.59 Thousand USD | -165.23% |
| 2004 Q4 | -1.28 Million USD | -947.94% |
| 2004 Q3 | -122.21 Thousand USD | -89.46% |
| 2004 Q2 | -64.5 Thousand USD | -54.93% |
| 2004 Q1 | -41.63 Thousand USD | 68.32% |
| 2004 FY | -1.5 Million USD | -934.54% |
| 2003 Q4 | -131.42 Thousand USD | -896.69% |
| 2003 FY | -145.86 Thousand USD | -208.41% |
| 2003 Q2 | - USD | 100.0% |
| 2003 Q1 | -1259.00 USD | 95.35% |
| 2003 Q3 | -13.18 Thousand USD | 0.0% |
| 2002 Q4 | -27.08 Thousand USD | -4610.09% |
| 2002 Q1 | -2545.00 USD | -100.77% |
| 2002 Q3 | -575.00 USD | 96.64% |
| 2002 FY | -47.29 Thousand USD | -115.48% |
| 2002 Q2 | -17.09 Thousand USD | -571.67% |
| 2001 Q3 | -11.87 Thousand USD | -86.08% |
| 2001 FY | 305.48 Thousand USD | 0.0% |
| 2001 Q4 | 330.9 Thousand USD | 2887.7% |
| 2001 Q2 | -6379.00 USD | 10.98% |
| 2001 Q1 | -7166.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -257.127% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 31.701% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 109.002% |
| Nascent Biotech, Inc. | -2.08 Million USD | -128.444% |
| Rebus Holdings, Inc. | -1.02 Million USD | -367.567% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 107.322% |
| Qrons Inc. | -789.34 Thousand USD | -504.194% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -654.133% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 92.381% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1047.877% |
| Skye Bioscience, Inc. | -37.64 Million USD | 87.331% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 93.638% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 27.477% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1644.386% |
| SQZ Biotechnologies Company | -79.46 Million USD | 93.998% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -64.887% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -161.967% |
| Mesoblast Limited | -87.95 Million USD | 94.578% |
| Marizyme, Inc. | -65.34 Million USD | 92.702% |
| Genus plc | 7.9 Million USD | 160.369% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 56.213% |
| Pharming Group N.V. | -10.54 Million USD | 54.786% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -119.797% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -28.541% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 46.074% |
| ContraFect Corporation | -65.15 Million USD | 92.68% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 2.392% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -176.082% |
| IMV Inc. | -36.48 Million USD | 86.929% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 40.827% |
| MultiCell Technologies, Inc. | -380.07 USD | -1254718.06% |
| ONE Bio Corp. | 8.67 Million USD | 154.966% |
| Accustem Sciences Inc. | -3.74 Million USD | -27.3% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 90.774% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -276.376% |
| Q BioMed Inc. | -2.05 Million USD | -132.406% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -27.757% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -100.313% |
| Biomind Labs Inc. | -1.21 Million USD | -292.746% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 92.015% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -53.757% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 39.654% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -144.668% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -31745.533% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 69.951% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 18.017% |
| GB Sciences, Inc. | -1.36 Million USD | -250.244% |
| Alpha Cognition Inc. | -13.77 Million USD | 65.372% |
| HST Global, Inc. | -146.21 Thousand USD | -3161.875% |
| CSL Limited | 2.64 Billion USD | 100.181% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -171.784% |
| Halberd Corporation | -79.67 Thousand USD | -5885.726% |
| Enzolytics Inc. | -2.17 Million USD | -119.088% |
| Agentix Corp. | -1.37 Million USD | -247.049% |
| Resverlogix Corp. | -3.61 Million USD | -32.11% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -50.379% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.384% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 4966.517% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 168.873% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -20.04% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -57.6% |
| AVAX Technologies, Inc. | -6.41 Million USD | 25.64% |
| Zenith Capital Corp. | -10.59 Million USD | 54.991% |
| Genscript Biotech Corporation | -95.47 Million USD | 95.005% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -20419.693% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -15.033% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -7790.7% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -137.851% |
| Kadimastem Ltd | -3.3 Million USD | -44.198% |
| Helix BioMedix, Inc. | -1.05 Million USD | -351.603% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -24.881% |
| BioStem Technologies, Inc. | -8.48 Million USD | 43.779% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -980.544% |
| LadRx Corporation | 400.44 Thousand USD | 1290.978% |
| Cell Source, Inc. | -5.32 Million USD | 10.374% |
| Regen BioPharma, Inc. | 1.02 Million USD | 565.965% |
| Regen BioPharma, Inc. | 1.02 Million USD | 565.965% |
| Affymax, Inc. | -14.42 Million USD | 66.936% |
| Itoco Inc. | -1.86 Million USD | -155.174% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -7.353% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -185.751% |
| Mobile Lads Corp. | -2.26 Million USD | -110.719% |
| CytoDyn Inc. | -49.84 Million USD | 90.431% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -5934.425% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1990.584% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -406.536% |
| SYBLEU INC | -180.3 Thousand USD | -2545.081% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -195.72% |
| International Stem Cell Corporation | -131 Thousand USD | -3540.601% |
| Bioxytran, Inc. | -4.28 Million USD | -11.43% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -8687.564% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -88.487% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 90.079% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -125.6% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -510.74% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -50.543% |
| Neutra Corp. | -233.46 Thousand USD | -1942.785% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 76.496% |
| PureTech Health plc | -65.69 Million USD | 92.741% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 77.574% |
| IXICO plc | -1.17 Million USD | -304.855% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 51.957% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 91.652% |
| CSL Limited | 2.64 Billion USD | 100.181% |
| Cellectis S.A. | -103.17 Million USD | 95.378% |